-
1
-
-
33646560022
-
Systematic therapy for ovarian cancer: Current status and new treatments
-
Ozols RF. Systematic therapy for ovarian cancer: Current status and new treatments. Semin Oncol 2006;33:S3-11.
-
(2006)
Semin Oncol
, vol.33
-
-
Ozols, R.F.1
-
3
-
-
0024511529
-
The CA 125 tumour-associated antigen: A review of the literature
-
Jacobs I, Bast RC Jr. The CA 125 tumor-associated antigen: A review of the literature. Hum Reprod 1989;4:1-12. (Pubitemid 19069900)
-
(1989)
Human Reproduction
, vol.4
, Issue.1
, pp. 1-12
-
-
Jacobs, I.1
Bast Jr., R.C.2
-
4
-
-
0037116832
-
Use of proteomic patterns in serum to identify ovarian cancer
-
DOI 10.1016/S0140-6736(02)07746-2
-
Petricoin EF III, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359:572-7. (Pubitemid 34178440)
-
(2002)
Lancet
, vol.359
, Issue.9306
, pp. 572-577
-
-
Petricoin III, E.F.1
Ardekani, A.M.2
Hitt, B.A.3
Levine, P.J.4
Fusaro, V.A.5
Steinberg, S.M.6
Mills, G.B.7
Simone, C.8
Fishman, D.A.9
Kohn, E.C.10
Liotta, L.A.11
-
5
-
-
35848962931
-
How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design
-
DOI 10.1016/j.jclinepi.2007.04.020, PII S0895435607002831
-
Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: Roles of phases, guidelines, and study design. J Clin Epidemiol 2007;60:1205-19. (Pubitemid 350061148)
-
(2007)
Journal of Clinical Epidemiology
, vol.60
, Issue.12
, pp. 1205-1219
-
-
Ransohoff, D.F.1
-
6
-
-
0025240758
-
Cloning and analysis of mRNAs expressed specifically in the human epididymis
-
Kirchhoff C, Osterhoff C, Habben I, Ivell R. Cloning and analysis of mRNA expressed specifically in the human epididymis. Int J Androl 1990;13:155-67. (Pubitemid 20116937)
-
(1990)
International Journal of Andrology
, vol.13
, Issue.2
, pp. 155-167
-
-
Kirchloff, C.1
Osterhoff, C.2
Habben, I.3
Ivell, R.4
-
7
-
-
10744220410
-
Gene Expression Patterns in Ovarian Carcinomas
-
DOI 10.1091/mbc.E03-05-0279
-
Schaner ME, Ross DT, Ciavarino G. Gene expression patterns in ovarian carcinomas. Mol Biol Cell 2003;14:4376-86. (Pubitemid 37444641)
-
(2003)
Molecular Biology of the Cell
, vol.14
, Issue.11
, pp. 4376-4386
-
-
Schaner, M.E.1
Ross, D.T.2
Ciaravino, G.3
Sorlie, T.4
Troyanskaya, O.5
Diehn, M.6
Wang, Y.C.7
Duran, G.E.8
Sikic, T.L.9
Caldeira, S.10
Skomedal, H.11
Tu, I.-P.12
Hernandez-Boussard, T.13
Johnson, S.W.14
O'Dwyer, P.J.15
Fero, M.J.16
Kristensen, G.B.17
Borresen-Dale, A.-L.18
Hastie, T.19
Tibshirani, R.20
Van De Rijn, M.21
Teng, N.N.22
Longacre, T.A.23
Botstein, D.24
Brown, P.O.25
Sikic, B.I.26
more..
-
8
-
-
0038756386
-
The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma
-
Hellstrom I, Raycraft J, Hayde-Ledbetter M. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003;63:3695-700. (Pubitemid 36793054)
-
(2003)
Cancer Research
, vol.63
, Issue.13
, pp. 3695-3700
-
-
Helistrom, I.1
Raycraft, J.2
Hayden-Ledbetter, M.3
Ledbetter, J.A.4
Schummer, M.5
McIntosh, M.6
Drescher, C.7
Urban, N.8
Hellstrom, K.E.9
-
9
-
-
49249084432
-
Use of yeast-secreted in vivo biotinylated recombinanat antibodies (biobodies) in beadbased ELISA
-
Scholler N, Lowe KA, Bergan LA. Use of yeast-secreted in vivo biotinylated recombinanat antibodies (biobodies) in beadbased ELISA. Clin Cancer Res 2008;14:2647-55.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 2647-2655
-
-
Scholler, N.1
Lowe, K.A.2
Bergan, L.A.3
-
10
-
-
69949188760
-
HE4 as a biomarker for ovarian and endometrial cancer management
-
Li J, Dowdy S, Tipton T, Podratz K, Lu W-G, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 2009;9:555-66.
-
(2009)
Expert Rev Mol Diagn
, vol.9
, pp. 555-566
-
-
Li, J.1
Dowdy, S.2
Tipton, T.3
Podratz, K.4
Lu, W.-G.5
Xie, X.6
-
11
-
-
38649134531
-
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
-
DOI 10.1016/j.ygyno.2007.10.017, PII S0090825807008542
-
Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2007;108:402-8. (Pubitemid 351174295)
-
(2008)
Gynecologic Oncology
, vol.108
, Issue.2
, pp. 402-408
-
-
Moore, R.G.1
Brown, A.K.2
Miller, M.C.3
Skates, S.4
Allard, W.J.5
Verch, T.6
Steinhoff, M.7
Messerlian, G.8
DiSilvestro, P.9
Granai, C.O.10
Bast Jr., R.C.11
-
12
-
-
57649088474
-
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
-
Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009;112:40-6.
-
(2009)
Gynecol Oncol
, vol.112
, pp. 40-46
-
-
Moore, R.G.1
McMeekin, D.S.2
Brown, A.K.3
DiSilvestro, P.4
Miller, M.C.5
Allard, W.J.6
-
13
-
-
64949192073
-
Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
-
Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100:1315-9.
-
(2009)
Br J Cancer
, vol.100
, pp. 1315-1319
-
-
Huhtinen, K.1
Suvitie, P.2
Hiissa, J.3
Junnila, J.4
Huvila, J.5
Kujari, H.6
-
14
-
-
77956342398
-
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass
-
Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010;203:228.e1-5.
-
(2010)
Am J Obstet Gynecol
, vol.203
-
-
Moore, R.G.1
Jabre-Raughley, M.2
Brown, A.K.3
Robison, K.M.4
Miller, M.C.5
Allard, W.J.6
-
15
-
-
79952784426
-
The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: Is it really useful?
-
Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati G, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: Is it really useful? Clin Chem Lab Med 2011;49:521-5.
-
(2011)
Clin Chem Lab Med
, vol.49
, pp. 521-525
-
-
Montagnana, M.1
Danese, E.2
Ruzzenente, O.3
Bresciani, V.4
Nuzzo, T.5
Gelati, G.6
-
16
-
-
79952801158
-
Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: A prospective case-control study in a Korean population
-
Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: A prospective case-control study in a Korean population. Clin Chem Lab Med 2011;49:527-34.
-
(2011)
Clin Chem Lab Med
, vol.49
, pp. 527-534
-
-
Kim, Y.M.1
Whang, D.H.2
Park, J.3
Kim, S.H.4
Lee, S.W.5
Park, H.A.6
-
17
-
-
7044233360
-
Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?
-
DOI 10.1200/JCO.2004.10.028
-
Grolund B. Høgdall C, Hilden J, Engelholm SA, Høgdall EVS, Hansen HH. Should CA125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004;22:4051-8. (Pubitemid 41199651)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.20
, pp. 4051-4058
-
-
Gronlund, B.1
Hogdall, C.2
Hilden, J.3
Engelholm, S.A.4
Hogdall, E.V.S.5
Hansen, H.H.6
|